“…Over the years we designed a variety of GSH mimics and derivatives characterized by amino acid substitution and/or bioisosteric replacements of the g-glutamyl linkage, addressed to enhance both metabolic resistance and affinity to GST binding sites, through the attribution of specific chemical and conformational properties to the modified GSH backbone [27][28][29][30][31][32][33][34] . Among these, the g-oxa-glutamyl (Glo) analog of GSH, H-Glo[Cys-Gly-OH]-OH, deserves particular attention for more than one reason: (1) as expected, the replacement of the scissile g-glutamyl-cysteinyl peptide bond with the OCONH unit assures resistance to g-GTmediated hydrolysis 29,35 ; (2) the substitution does not sensibly alter the physico-chemical properties of the tripeptide; (3) groups crucial for binding to the G-site resemble those of the natural ligand, with the H-bond donor/acceptor potential of the GSH backbone fairly maintained and (4) more importantly, S-conjugates of this urethane mimic of glutathione have been shown to inhibit MRP1 36 . Thus we report here a straight preparation of the glutathione conjugate H-Glu[Cys(NBD)-Gly-OH]-OH (GS-NBD, 1) and the synthesis of its new analog H-Glo[Cys(NBD)-Gly-OH]-OH or (OCONH) GS-NBD (5), to be comparatively evaluated as inhibitors of human GSTP1-1 and M2-2.…”